Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
One Percent Rule Checklist For Safer Forex Trading Risk 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
GAITHERSBURG, Md., April 20, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 4, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2017, recent business developments, revenue guidance for the second quarter of 2017, and revenue and net income guidance for full year 2017.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in: (262) 912-6157 Conference ID: 29691796 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/523ryq7t for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
